Medical/Pharmaceuticals APAC News & Press Release Distribution

Medical/Pharmaceuticals

All
Global

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

* As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS...

2026-07-15 08:00 3688

IMG Opens Applications for 2026 Fall Semester 'Student Journey Scholarship'

INDIANAPOLIS, July 13, 2026 /PRNewswire/ -- IMG (International Medical Group) is now accepting applications for itsStudent Journey Scholarship

2026-07-13 21:00 2555

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

* Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. * The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical ...

2026-07-13 20:30 2091

KLN Signs MOU with Advantech and YDCare to Support Digital Transformation of Hong Kong's Healthcare System

HONG KONG, July 13, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announced that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), has signed a tripartite Memorandum of Understanding (MOU) with Advantech Co., Ltd. ('Advantech'; Stock Code 2395.TW), a g...

2026-07-13 12:19 2985

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2026 LIFESTYLE PROGRAM IMPROVES BRAIN HEALTH AMONG OLDER ADULTS AT RISK FOR DEMENTIA ACROSS LATIN AMERICA

- LatAm-FINGERS Study Findings Confirm and Expand U.S. POINTER Trial Results - - Show Structured Dementia Risk Reduction Strategies Adaptable Across Cultures - Key Takeaways * The LatAm-FINGERS study shows lifestyle interventions adapted across Latin American cultures, health systems and commu...

2026-07-13 12:01 2549

Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB

SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-07-13 12:00 2751

AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities

* 873 employees volunteered more than 3,600 hours across 7 Asian markets to support local communities. * Employees partnered with 21 community organizations, positively impacting more than 4,300 people through initiatives focused on patient support, inclusion, education and environmental su...

2026-07-13 10:00 2628

AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2026

FORMER ELITE SOCCER PLAYERS SHOW EVIDENCE OF BRAIN HEALTH CHANGES IN MID-LIFE Key Takeaways * New research provides insights into brain health among former elite professional soccer players during midlife. * Former players reported high levels of depression, anxiety, and subjective difficult...

2026-07-12 12:01 3245

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo

HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June 30 in...

2026-07-09 08:00 4064

MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis

U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative d...

2026-07-08 10:43 3160

Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence

* Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks * Mean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacy * Up to 84% of weight loss was driven by reductions in fat mass, supporting meaningful improv...

2026-07-08 09:22 2641

Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence

Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma

EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, has received the American Chemical Society's 2026 Green Chem...

2026-07-07 20:00 3008

HKSH's First-in-Asia Comparative Study on Radiotherapy for Breast Cancer Reveals Hypofractionated Proton Therapy Prevents Breast Cancer Recurrence with 100% Survival Rate

Minimises Cardiopulmonary Concerns and Maintains Quality of Life HONG KONG, July 7, 2026 /PRNewswire/ -- The HKSH Cancer Centre under HKSH Medical Group (HKSH) introduced proton therapy in 2023, covering a wide range of cancer types including breast, prostate as well as head and neck cancers, an...

2026-07-07 19:27 3541

$HKSH's First-in-Asia Comparative Study on Radiotherapy for Breast Cancer Reveals Hypofractionated Proton Therapy Prevents Breast Cancer Recurrence with 100% Survival Rate$

Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases

BIRMINGHAM, England, July 7, 2026 /PRNewswire/ -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed financing round led by Empirical Ventures, with p...

2026-07-07 19:07 2475

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the closing of its previously announc...

2026-07-07 18:53 3421

ESHRE 42nd Annual Meeting: Halving fertility treatment costs could more than double births, major global study shows

A landmark international study has found that halving patient out-of-pocket costs was associated with a 2.67-fold increase in births achieved through assisted reproductive technology (ART). LONDON, July 7, 2026 /PRNewswire/ -- Presented at the 42nd Annual Meeting of the European Society of Human...

2026-07-07 07:01 2553

Gene Solutions' SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight

A blood-based cancer screening technology developed in Asia is gaining international attention after real-world data from more than 84,145 individuals were presented at ASCO Breakthrough 2026 and highlighted by the American Society of Clinical Oncology. For Gene Solutions, this milestone under...

2026-07-07 06:00 4558

Gene Solutions' SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight

Smarter, Lighter, & Construction-Free: Egg Medical Debuts EggNest® Complete 2.0 for Interventional Labs

MINNEAPOLIS, July 6, 2026 /PRNewswire/ -- Egg Medical , a leader inEnhanced Radiation Protection Devices

2026-07-06 22:12 3294

Smarter, Lighter, & Construction-Free: Egg Medical Debuts EggNest® Complete 2.0 for Interventional Labs

TMRW Vault® Receives CE Mark Under the European Medical Device Regulation (MDR)

WILMINGTON, Del., July 6, 2026 /PRNewswire/ -- Reprotech today announced that the TMRW Vault® has received CE marking as a Class IIa medical device under Regulation (EU) 2017/745, supporting commercialization in the European Union and other international markets that recognize the CE mark.

2026-07-06 21:02 2962

TMRW Vault® Receives CE Mark Under the European Medical Device Regulation (MDR)

Dx&Vx (DXVX) Partners with Over 40 Global Companies at BIO USA, "Focused Discussions on Overseas Out-Licensing Deals"

* Oral obesity drug with world-first mechanism of action unveiled, drawing strong on-site interest * Following successful Phase 1 clinical results, global discussions on OVM-200 expand * Meetings with over 40 companies, including major pharmaceutical companies, out-licensing now within reac...

2026-07-06 20:30 4819

Dx&Vx (DXVX) Partners with Over 40 Global Companies at BIO USA,

1 2 345 6 7 ... 387

Week's Top Stories

Most Reposted

Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub

[Picked up by 309 media titles]

2026-07-30 10:45